Evaluation of [ 18 F]F-PTTP as a Positron Emission Tomography Radioligand for Imaging P2X7 Receptors in Epileptic Rats
Molecular Pharmaceutics · 2025
DOI: 10.1021/acs.molpharmaceut.4c01458 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Wenhui Fu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China. Hauptthemen laut MEDLINE: Receptors, Purinergic P2X7, Positron-Emission Tomography, Epilepsy, Fluorine Radioisotopes. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Shanghai Rising-Star Program.
Abstract (Originalsprache)
Patients with epilepsy often face significant challenges, with one-third of them being resistant to available antiseizure medications, leading to drug-resistant epilepsy (DRE). The P2X7 receptor (P2X7R), a mechanistic and inflammatory biomarker, exhibits increased expression during epileptogenesis. P2X7R antagonists effectively reduce the severity of seizure and neuronal death, highlighting this receptor as a potential therapeutic target. Precise detection of P2X7R is essential for guiding the treatments. Herein, we prepared the P2X7R-targeting probe [18F]F-PTTP and evaluated its efficacy in positron emission tomography (PET) imaging of epileptic rats. [18F]F-PTTP was synthesized via the cleavage of the trifluoromethylsulfonyl group with a radiochemical yield of 10-17% (end of synthesis, EOS), molar activity of 56.12 ± 6.06 GBq/μmol (EOS), and radiochemical purity exceeding 99%. [18F]F-PTTP PET imaging was performed on epileptic rats induced via intrahippocampal kainic acid (KA) injection across three disease progression stages: acute (1 day), latent (1 week), and chronic (1 month). PET results revealed specific [18F]F-PTTP binding to the epileptic brain, particularly in the right hippocampus (KA-injected site), with the highest standardized uptake value ratio observed at 1 week (1.34 ± 0.11). Autoradiography and histological analyses confirmed P2X7R overexpression in the epileptic brain, associated with microglia and astrocyte activation. Our findings suggest that [18F]F-PTTP PET imaging is a promising tool for visualizing P2X7R expression during epileptogenesis, which may facilitate neuroinflammation assessment, P2X7R-targeted therapy, and treatment monitoring in epilepsy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
- Institute of Nuclear Medicine, Fudan University, Shanghai 200032, China.
- Shanghai Institute of Medical Imaging, Shanghai 200032, China.
- Department of Neurology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
ORCID-Profile: Wenhui Fu, Dai Shi, Dengfeng Cheng
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Shanghai Rising-Star Program
Zitieren
APA
Fu, W., Fu, Z., Shi, D., Yang, T., Ma, P., Su, H., Tong, F., Tan, H., Lin, Q., & Cheng, D. (2025). Evaluation of [ 18 F]F-PTTP as a Positron Emission Tomography Radioligand for Imaging P2X7 Receptors in Epileptic Rats. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c01458
Vancouver
Fu W, Fu Z, Shi D, Yang T, Ma P, Su H, et al. Evaluation of [ 18 F]F-PTTP as a Positron Emission Tomography Radioligand for Imaging P2X7 Receptors in Epileptic Rats. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.4c01458
BibTeX
@article{Fu2025,
author = {Fu, Wenhui and Fu, Zhequan and Shi, Dai and Yang, Tingting and Ma, Pengcheng and Su, Hongxing and Tong, Fangchao and Tan, Hui and Lin, Qingyu and Cheng, Dengfeng},
title = {Evaluation of [ 18 F]F-PTTP as a Positron Emission Tomography Radioligand for Imaging P2X7 Receptors in Epileptic Rats},
journal = {Molecular Pharmaceutics},
year = {2025},
doi = {10.1021/acs.molpharmaceut.4c01458}
}
EUVIMED